379 related articles for article (PubMed ID: 35305720)
1. Clostridioides difficile: Current overview and future perspectives.
Giles J; Roberts A
Adv Protein Chem Struct Biol; 2022; 129():215-245. PubMed ID: 35305720
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
3. Frontiers in antibiotic alternatives for
Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T
World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784
[No Abstract] [Full Text] [Related]
4. SER-109 (VOWST
Blair HA
Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Inflammation Reversibly Alters the Microbiota to Drive Susceptibility to Clostridioides difficile Colonization in a Mouse Model of Colitis.
Barron MR; Sovacool KL; Abernathy-Close L; Vendrov KC; Standke AK; Bergin IL; Schloss PD; Young VB
mBio; 2022 Aug; 13(4):e0190422. PubMed ID: 35900107
[TBL] [Abstract][Full Text] [Related]
6. The microbial metabolite urolithin A reduces
Ghosh S; Erickson D; Chua MJ; Collins J; Jala VR
mSystems; 2024 Feb; 9(2):e0125523. PubMed ID: 38193707
[No Abstract] [Full Text] [Related]
7. Current and future trends in clostridioides (clostridium) difficile infection management.
Khanna S; Gerding DN
Anaerobe; 2019 Aug; 58():95-102. PubMed ID: 31054313
[TBL] [Abstract][Full Text] [Related]
8. Advances in the diagnosis and treatment of Clostridium difficile infections.
Peng Z; Ling L; Stratton CW; Li C; Polage CR; Wu B; Tang YW
Emerg Microbes Infect; 2018 Feb; 7(1):15. PubMed ID: 29434201
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).
Bouza E; Aguado JM; Alcalá L; Almirante B; Alonso-Fernández P; Borges M; Cobo J; Guardiola J; Horcajada JP; Maseda E; Mensa J; Merchante N; Muñoz P; Pérez Sáenz JL; Pujol M; Reigadas E; Salavert M; Barberán J
Rev Esp Quimioter; 2020 Apr; 33(2):151-175. PubMed ID: 32080996
[TBL] [Abstract][Full Text] [Related]
11. Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives.
Cymbal M; Chatterjee A; Baggott B; Auron M
Am J Med; 2024 Jul; 137(7):571-576. PubMed ID: 38508330
[TBL] [Abstract][Full Text] [Related]
12. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
13. Clostridioides difficile infections; new treatments and future perspectives.
Normington C; Chilton CH; Buckley AM
Curr Opin Gastroenterol; 2024 Jan; 40(1):7-13. PubMed ID: 37942659
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activity of Tannic Acid
Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
[TBL] [Abstract][Full Text] [Related]
15. Cutting edges in Clostridioides difficile infections.
Durovic A; Tschudin-Sutter S
Swiss Med Wkly; 2021 Sep; 151():w30033. PubMed ID: 34652093
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
Berry P; Khanna S
BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938
[TBL] [Abstract][Full Text] [Related]
17. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
Khanna S
J Intern Med; 2021 Aug; 290(2):294-309. PubMed ID: 33856727
[TBL] [Abstract][Full Text] [Related]
18. Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis.
Cappetto CM
Am J Health Syst Pharm; 2021 Jul; 78(15):1374-1381. PubMed ID: 33851215
[TBL] [Abstract][Full Text] [Related]
19. [Clostridioides difficile - New Insights and Therapy Recommendations].
Schönherr S; Jung L; Lübbert C
Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
[TBL] [Abstract][Full Text] [Related]
20. An insight into
Thabit AK; Aljedaani HJ; Alghamdi RH; Badahdah RM; Lashkar MO; Alnajjar A
Expert Rev Gastroenterol Hepatol; 2023; 17(8):805-810. PubMed ID: 37480286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
